| Autor: |
Sauerbier A; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, 50937 Cologne, Germany.; Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK., Bachon P; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, 50937 Cologne, Germany., Ambrosio L; NIHR Applied Research Collaboration Wessex, School of Health Sciences, University of Southampton, Southampton SO17 1BJ, UK., Loehrer PA; Department of Neurology, University Hospital Giessen and Marburg, Campus Marburg, 35043 Marburg, Germany., Rizos A; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, 50937 Cologne, Germany.; Parkinson Foundation International Centre of Excellence, King's College Hospital, London SE5 8AF, UK., Jost ST; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, 50937 Cologne, Germany., Gronostay A; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, 50937 Cologne, Germany., Fink GR; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, 50937 Cologne, Germany.; Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Centre Jülich, 52428 Jülich, Germany., Ashkan K; Parkinson Foundation International Centre of Excellence, King's College Hospital, London SE5 8AF, UK., Nimsky C; Department of Neurosurgery, University Marburg, 35043 Marburg, Germany., Visser-Vandewalle V; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Stereotactic and Functional Neurosurgery, 50937 Cologne, Germany., Chaudhuri KR; Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.; Parkinson Foundation International Centre of Excellence, King's College Hospital, London SE5 8AF, UK., Timmermann L; Department of Neurology, University Hospital Giessen and Marburg, Campus Marburg, 35043 Marburg, Germany., Martinez-Martin P; Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, 28029 Madrid, Spain., Dafsari HS; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, 50937 Cologne, Germany. |
| Abstrakt: |
The effect of subthalamic stimulation (STN-DBS) on patients' personal satisfaction with life and their Parkinson's disease (PD) treatment is understudied, as is its correlation with quality of life (QoL). Therefore, we tested the hypothesis that STN-DBS for PD enhances satisfaction with life and treatment. In a prospective, multicenter study with a 6-month follow-up involving 121 patients, we measured the main outcomes using the Satisfaction with Life and Treatment Scale (SLTS-7). Secondary outcomes included the eight-item PD Questionnaire (PDQ-8), European QoL Questionnaire (EQ-5D-3L), EQ-Visual Analogue Scale (VAS), Non-Motor Symptom Scale (NMSS), Hospital Anxiety and Depression Scale (HADS), and Unified PD Rating Scale (UPDRS). Longitudinal outcome changes, effect sizes (Cohen's d), and correlations between outcome changes were analyzed. SLTS-7 scores improved at the 6-month follow-up, particularly in the domains of 'satisfaction with physical health' and 'satisfaction with treatment'. Change scores correlated strongly (EQ-VAS), moderately (PDQ-8 SI and HADS), and weakly (UPDRS-activities of daily living and EQ-5D-3L) with other scales. Satisfaction with physical health, psychosocial well-being, or treatment was not related to UPDRS-motor examination. This study provides evidence that STN-DBS enhances patients' personal satisfaction with life and treatment. This satisfaction is associated with improvements in the QoL, daily activities, and neuropsychiatric aspects of PD rather than its motor aspects. |
